August 1, 2022
Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease
May 16, 2022
Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease
January 6, 2022
Zenas BioPharma Appoints Dr. John Orloff to Board of Directors
November 21, 2021
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
May 3, 2021
Zenas BioPharma Announces New Executive Leadership Appointments
March 23, 2021
Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies
